Gastrointestinal symptoms and the severity of COVID-19: Disorders of gut-brain interaction are an outcome.
COVID-19
anxiety
depression
gastrointestinal/digestive symptoms
patient clustering
post-COVID disorders of gut-brain interaction (DGBI)
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
24
02
2022
received:
04
11
2021
accepted:
17
03
2022
pubmed:
7
4
2022
medline:
31
8
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Many of the studies on COVID-19 severity and its associated symptoms focus on hospitalized patients. The aim of this study was to investigate the relationship between acute GI symptoms and COVID-19 severity in a clustering-based approach and to determine the risks and epidemiological features of post-COVID-19 Disorders of Gut-Brain Interaction (DGBI) by including both hospitalized and ambulatory patients. The study utilized a two-phase Internet-based survey on: (1) COVID-19 patients' demographics, comorbidities, symptoms, complications, and hospitalizations and (2) post-COVID-19 DGBI diagnosed according to Rome IV criteria in association with anxiety (GAD-7) and depression (PHQ-9). Statistical analyses included univariate and multivariate tests. Five distinct clusters of symptomatic subjects were identified based on the presence of GI symptoms, loss of smell, and chest pain, among 1114 participants who tested positive for SARS-CoV-2. GI symptoms were found to be independent risk factors for severe COVID-19; however, they did not always coincide with other severity-related factors such as age >65 years, diabetes mellitus, and Vitamin D deficiency. Of the 164 subjects with a positive test who participated in Phase-2, 108 (66%) fulfilled the criteria for at least one DGBI. The majority (n = 81; 75%) were new-onset DGBI post-COVID-19. Overall, 86% of subjects with one or more post-COVID-19 DGBI had at least one GI symptom during the acute phase of COVID-19, while 14% did not. Depression (65%), but not anxiety (48%), was significantly more common in those with post-COVID-19 DGBI. GI symptoms are associated with a severe COVID-19 among survivors. Long-haulers may develop post-COVID-19 DGBI. Psychiatric disorders are common in post-COVID-19 DGBI.
Sections du résumé
BACKGROUND
Many of the studies on COVID-19 severity and its associated symptoms focus on hospitalized patients. The aim of this study was to investigate the relationship between acute GI symptoms and COVID-19 severity in a clustering-based approach and to determine the risks and epidemiological features of post-COVID-19 Disorders of Gut-Brain Interaction (DGBI) by including both hospitalized and ambulatory patients.
METHODS
The study utilized a two-phase Internet-based survey on: (1) COVID-19 patients' demographics, comorbidities, symptoms, complications, and hospitalizations and (2) post-COVID-19 DGBI diagnosed according to Rome IV criteria in association with anxiety (GAD-7) and depression (PHQ-9). Statistical analyses included univariate and multivariate tests.
RESULTS
Five distinct clusters of symptomatic subjects were identified based on the presence of GI symptoms, loss of smell, and chest pain, among 1114 participants who tested positive for SARS-CoV-2. GI symptoms were found to be independent risk factors for severe COVID-19; however, they did not always coincide with other severity-related factors such as age >65 years, diabetes mellitus, and Vitamin D deficiency. Of the 164 subjects with a positive test who participated in Phase-2, 108 (66%) fulfilled the criteria for at least one DGBI. The majority (n = 81; 75%) were new-onset DGBI post-COVID-19. Overall, 86% of subjects with one or more post-COVID-19 DGBI had at least one GI symptom during the acute phase of COVID-19, while 14% did not. Depression (65%), but not anxiety (48%), was significantly more common in those with post-COVID-19 DGBI.
CONCLUSION
GI symptoms are associated with a severe COVID-19 among survivors. Long-haulers may develop post-COVID-19 DGBI. Psychiatric disorders are common in post-COVID-19 DGBI.
Identifiants
pubmed: 35383423
doi: 10.1111/nmo.14368
pmc: PMC9115309
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14368Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Gut. 2020 Aug;69(8):1543-1544
pubmed: 32312790
Am J Gastroenterol. 2020 Jun;115(6):916-923
pubmed: 32301761
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Am J Gastroenterol. 2021 Jan 1;116(1):4-7
pubmed: 33273261
Gastroenterology. 2020 Aug;159(2):765-767.e2
pubmed: 32333911
Am J Gastroenterol. 2021 Feb 1;116(2):306-310
pubmed: 33009054
Am J Gastroenterol. 2020 Jul;115(7):1129-1132
pubmed: 32618665
Gastroenterology. 2019 Jan;156(1):46-58.e7
pubmed: 30009817
J Med Virol. 2021 Jan;93(1):336-350
pubmed: 32681674
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):168-176
pubmed: 33470700
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Rev Gastroenterol Mex (Engl Ed). 2020 Jul - Sep;85(3):282-287
pubmed: 32376072
Gastroenterology. 2021 Jan;160(1):99-114.e3
pubmed: 32294476
J Asthma. 2022 Jun;59(6):1188-1194
pubmed: 33863266
Gastroenterology. 2020 Sep;159(3):1137-1140.e2
pubmed: 32389667
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
J Clin Virol. 2020 Jun;127:104371
pubmed: 32315817
J Clin Gastroenterol. 2022 Apr 1;56(4):285-298
pubmed: 35125404
Crit Rev Food Sci Nutr. 2022;62(5):1308-1316
pubmed: 33146028
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283
pubmed: 33589829
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
Neurogastroenterol Motil. 2022 Sep;34(9):e14368
pubmed: 35383423
BMJ Open Gastroenterol. 2021 Mar;8(1):
pubmed: 33664052
J Gastroenterol Hepatol. 2022 Mar;37(3):489-498
pubmed: 34672022
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Proc (Bayl Univ Med Cent). 2020 May 29;33(3):366-369
pubmed: 32669979
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Gastroenterology. 2020 Aug;159(2):775-777
pubmed: 32283101
J Gastroenterol. 2021 May;56(5):409-420
pubmed: 33759041
Neurogastroenterol Motil. 2022 Mar;34(3):e14251
pubmed: 34468069
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Ann Gastroenterol. 2020 Nov-Dec;33(6):615-630
pubmed: 33162738
Medicine (Baltimore). 2020 Nov 25;99(48):e23327
pubmed: 33235096
Gastroenterology. 2020 Jun;158(8):2298-2301.e7
pubmed: 32234303
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Mayo Clin Proc. 2020 Aug;95(8):1632-1648
pubmed: 32753138
Aliment Pharmacol Ther. 2019 Jul;50(2):132-143
pubmed: 31157418
Lancet Gastroenterol Hepatol. 2021 May;6(5):344-346
pubmed: 33711290
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
Cleve Clin J Med. 2021 Feb 17;:
pubmed: 32554734
Gastroenterology. 2020 Jul;159(1):373-375.e2
pubmed: 32294477
JGH Open. 2020 Nov 21;5(1):107-115
pubmed: 33363257
Gastroenterology. 2020 Jul;159(1):320-334.e27
pubmed: 32407808
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937